1. Home
  2. EYPT vs MMD Comparison

EYPT vs MMD Comparison

Compare EYPT & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • MMD
  • Stock Information
  • Founded
  • EYPT 1987
  • MMD 2012
  • Country
  • EYPT United States
  • MMD United States
  • Employees
  • EYPT N/A
  • MMD N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • MMD Investment Managers
  • Sector
  • EYPT Industrials
  • MMD Finance
  • Exchange
  • EYPT Nasdaq
  • MMD Nasdaq
  • Market Cap
  • EYPT 439.4M
  • MMD 462.2M
  • IPO Year
  • EYPT 2005
  • MMD N/A
  • Fundamental
  • Price
  • EYPT $9.17
  • MMD $16.40
  • Analyst Decision
  • EYPT Strong Buy
  • MMD
  • Analyst Count
  • EYPT 8
  • MMD 0
  • Target Price
  • EYPT $27.29
  • MMD N/A
  • AVG Volume (30 Days)
  • EYPT 1.1M
  • MMD 74.7K
  • Earning Date
  • EYPT 11-07-2024
  • MMD 01-01-0001
  • Dividend Yield
  • EYPT N/A
  • MMD 4.88%
  • EPS Growth
  • EYPT N/A
  • MMD N/A
  • EPS
  • EYPT N/A
  • MMD N/A
  • Revenue
  • EYPT $45,713,000.00
  • MMD N/A
  • Revenue This Year
  • EYPT N/A
  • MMD N/A
  • Revenue Next Year
  • EYPT N/A
  • MMD N/A
  • P/E Ratio
  • EYPT N/A
  • MMD N/A
  • Revenue Growth
  • EYPT 7.50
  • MMD N/A
  • 52 Week Low
  • EYPT $5.86
  • MMD $14.30
  • 52 Week High
  • EYPT $30.99
  • MMD $17.67
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 38.25
  • MMD 34.19
  • Support Level
  • EYPT $11.26
  • MMD $16.51
  • Resistance Level
  • EYPT $12.23
  • MMD $16.77
  • Average True Range (ATR)
  • EYPT 0.97
  • MMD 0.09
  • MACD
  • EYPT -0.30
  • MMD -0.00
  • Stochastic Oscillator
  • EYPT 3.24
  • MMD 0.00

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund

MainStay MacKay DefinedTerm Municipal Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company may also invest in TOB (Tender Option Bonds) Floaters and TOB Residuals issued by the TOB Issuer. It evaluates its performance against Barclays Municipal Bond Index.

Share on Social Networks: